Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: A critical reappraisal of molecular strategies

Leukemia

Volumn 13, Issue 11, 1999, Pages 1691-1695

  Corradini, P ^a   Ladetto, M ^b   Pileri, A ^b   Tarella, C ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Minimal residual disease in lymphomas

Indexed keywords

ANTINEOPLASTIC ACTIVITY; BONE MARROW TRANSPLANTATION; CHEMOTHERAPY; DIAGNOSTIC PROCEDURE; DRUG MEGADOSE; EARLY DIAGNOSIS; HUMAN; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW;

EID: 0032718332     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401559     Document Type: Review

References (52)

1. Armitage JO. Bone marrow transplantation for indolent lymphomas. Semin Oncol 1993; 20: 136-142.
2. Coiffier B. Towards a cure in indolent lymphoproliferative diseases? Eur J Cancer 1995; 31A: 2135-2137.
3. Coiffier B, Philip T, Burnett AK, Symann ML. Consensus Conference on Intensive Chemotherapy Plus Hematopoietic Stem-Cell Transplantation in Malignancies: Lyon, France, June 4-6, 1993. J Clin Oncol 1994; 12: 226-231.
4. Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon N, Ritz J, Nadler LM. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780-2786.
5. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New Engl J Med 1997; 336: 1290-1297.
6. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
7. Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau JP, Espinouse D, Reyes F, Gisselbrecht C, Coiffier B. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257-3262.
8. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445-450.
9. Wright SJ, Robertson LE, O'Brien S, Plunkett W, Keating MJ. The role of fludarabine in hematological malignancies. Blood Rev 1994; 8: 125-134.
10. Leget G, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998; 10: 548-551.
11. Bensinger WI. Should we purge? Bone Marrow Transplant 1998; 21: 113-115.
12. Gee A. Purging of peripheral blood stem cell grafts. Stem Cells 1995; 13: 52-62.
13. Gorin NC, Lopez M, Laporte JP, Quittet P, Lesage S, Lemoine F, Berenson RJ, Isnard F, Grande M, Stachowiak J. Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood 1995; 85: 1647-1654.
14. Lopez M, Lemoine F, Firat H, Fouillard L, Laporte JP, Lesage S, Isnard F, Stachowiak J, Ferrer-Le Coeur F, Morel P, Najman A, Douay L, Gorin NC. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting. Blood 1997; 90: 2830-2838.
15. Lowenberg B, Voogt P. Autologous stem-cell transplantation and purging (editorial). J Clin Oncol 1996; 14: 2194-2196.
16. Gribben JG. Attainment of molecular remission: a worthwhile goal? J Clin Oncol 1994; 12: 1532-1534.
17. Scimè R, Indovina A, Santoro A, Musso M, Olivieri A, Tringali S, Crescimanno A, Montanari M, Felice R, Catania P, Mariani G, Leoni P, Majolino I. PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia. Bone Marrow Transplant 1998; 22: 1159-1165.
18. Provan D, Bartlett-Pandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P, Soiffer R, Ritz J, Nadler LM, Gribben JG. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996; 88: 2228-2235.
19. Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, Barber M, Saporito L, Woo SD, Coral F, Spector N, Rabinowe SN, Grossbard ML, Ritz J, Nadler LM. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-3457.
20. Corradini P, Astolfi M, Cherasco C, Ladetto M, Voena C, Caracciolo D, Pileri A, Tarella C. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89: 724-731.
21. Pappa V, Wilkes S, Salam A, Young B, Lister T, Rohatiner A. Use of the polymerase chain reaction and direct sequencing analysis to detect cells with the t(14;18) in autologous bone marrow from patients with follicular lymphoma, before and after in vitro treatment. Bone Marrow Transplant 1998; 22: 553-558.
22. Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, Nadler LM, Freedman AS, Gribben JG. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997; 90: 4212-4221.
23. Berinstein NL, Reis MD, Ngan BY, Sawka C, Jamal HH, Kuzniar B. Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma. J Clin Oncol 1993; 11: 1344-1352.
24. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. New Engl J Med 1991; 325: 1525-1533.
25. Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, Pileri A. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85: 1596-1602.
26. Voena C, Ladetto M, Astolfi M, Provan D, Gribben JG, Boccadoro M, Pileri A, Corradini P. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997; 11: 1793-1798.
27. Choi Y, Creenberg SJ, Du TL, Ward PM, Overturf PM, Brecher ML, Ballow M. Clonal evolution in B-lineage acute lymphoblastic leukemia by contemporaneous VH-VH gene replacements and VH-DJH gene rearrangements. Blood 1996; 87: 2506-2512.
28. Lee MS, Chang KS, Cabanillas F, Freireich E, Trujillo J, Stass SA. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 1999; 237: 175-178.
29. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985; 41: 899-906.
30. Cleary ML, Galili N, Sklar J. Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. J Exp Med 1986; 164: 315-320.
31. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985; 82: 7439-7443.
32. Tsujimoto Y, Yunis J, Onorato-Showe L, Erikson J, Nowell PC, Croce CM. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 1984; 224: 1403-1406.
33. Zwicky C, Maddocks A, Andersen NS, Gribben JG. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 1996; 88: 3314-3322.
34. Orlando C, Pinzani P, Pazzagli M. Developments in quantitative PCR. Clin Chem Lab Med 1998; 36: 255-269.
35. Luthra R, McBride JA, Cabanillas F, Sarris A. Novel 5′ exonuclease-based real-time PCR assay for the detection of t(14;18)(q32;q21) in patients with follicular lymphoma. Am J Pathol 1998; 153: 63-68.
36. Gerard CJ, Olsson K, Ramanatham R, Reading C, Hanania EG. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmidDNA complementarity determining region III standards. Cancer Res 1998; 58: 3957-3964.
37. Ladetto M, Donovan JW, Schlossman R, Anderson KC, Gribben JG. Limitations of quantitative detection of immunoglobulin heavy chain (1gH) gene rearrangements in multiple myeloma (MM) patients using real-time PCR. Blood 1998; 92: 286a.
38. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle JN. Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85-90.
39. Donovan JW, Andersen NS, Poor CM, Bowers D, Gribben JG. Prospective analysis of minimal residual disease detection in patients with CLL undergoing autologous and allogeneic BMT. Blood 1998; 92: 652a.
40. Di Nicola M, Siena S, Corradini P, Bregni M, Ruffini PA, Milanesi M, Tarella C, Gianni AM. Elimination of bcl-2-lgH positive follicular lymphoma cells from blood transplants with high recovery of hernatopoietic progenitors by the Miltenyi CD34+ cell sorting system. Bone Marrow Transplant 1996; 18: 1117.
41. Hardingham JE, Kotasek D, Sage RE, Cooley LT, Mi JX, Dobrovic A, Norman JE, Bolton AE. Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 1073-1079.
42. Moos M, Schulz R, Martin S, Haas R. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Leukemia 1998; 12: 1971-1976.
43. Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister FB, Rodriguez MA, Romaguera MA, Sarris A, Pugh WC, Lee MS. The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998; 91: 2955-2960.
44. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
45. Corradini P, Astolfi M, Voena C, Caracciolo D, Vitolo U, Benedetti G, Pileri A, Tarella C. High-dose chemotherapy and PBPC autografting inducedurable molecular remissions in follicular lymphomas but not in small lymphocytic and mantle cell lymphomas. Blood 1999; 92: 463a.
46. Gianni AM, Magni M, Di Nicola M, Gandola L, Lombardi F, Dastoli G, Matteucci P, Devizzi L, Bregni M, Campana S, Corradini P, Pileri A, Tarella C. In vivo purging of circulating CD34+ progenitor cells in low-grade lymphoma with Rituximab and high-dose chemotherapy. Blood 1999; 92: 119a.
47. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, Chaekal OK, Gale RP, Klein JP, Lazarus HM, McCarthy PL, Raemaekers JM, Reiffers J, Phillips GL, Schattenberg AV, Verdonk LF, Vose JM, Horowitz MM. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832-1836.
48. Verdonk LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 10: 4201-4205.
49. Corradini P, Ladetto M, Astolfi M, Voena C, Tarella C, Bacigalupo A, Pileri A. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. Br J Haematol 1996; 94: 376-378.
50. Mandingers CMPW, Meijerink JPP, Raemaekers JMM, Schattenberg AVMB, Mensink EJBM. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18). Lancet 1998; 352: 1522-1523.
51. Cross NC. Minimal residual disease in chronic myeloid leukaemia. Hematol Cell Ther 1998; 40: 224-228.
52. Diverio D, Rossi V, Avvisati G, DeSantis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco FL. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial. GIMEMA-AIEOP Multicenter 'AIDA' Trial. Blood 1998; 92: 784-789.